PLATFORM To design point-of-care systems that match the performance of reference laboratories, Claros relies on its multi-disciplinary competences in sciences and engineering that encompass: Rapid-cycle, high-precision injection molding Reliable solutions for long-term storage and delivery of biological reagents Automation of complex assay steps using micro-fluidic devices Integration of robust optical detection systems Access to most recent advances in hardware and software for communication between diagnostic devices, users, and medical records Claros is currently focused on urological maladies, specifically those associated with the prostate. Relying on an un-paralleled ease of use, the system is designed to operate in near-patient settings, such as a physician's office. The capability of the Claros platform to perform multiple tests simultaneously (multiplexing) can be exploited to include the analysis of existing and novel biomarkers to improve the overall quality of care in urology. The capabilities of the Claros technology inherently allows for applications beyond urology, especially for decentralized clinical testing. The platform nature of the Claros technology affords the opportunity to pursue several decentralized testing applications. These additional applications include but are not limited to female healthcare, metabolic disorders, thyroid disorders, ovulation, heart disease, infectious diseases and cancer. In addition, the Claros device can facilitate creation of diagnostic / therapeutic combinations in order to improve access for the patient to adequate therapies and monitor the use of therapeutics. Claros has validated its core technology for detection and quantitation of a number of proteins (i.e., multiplex assays on a single cartridge). In addition to tests for urology, Claros is working with partners to demonstrate the detection of infectious diseases such as HIV, hepatitis C, and syphilis in field settings in Africa. The Claros system has the capability of dramatically increasing the range of possible locations where diagnostic testing can be provided. As such, a strong opportunity exists to utilize the technology in extreme resource-poor settings to improve global health. In considering our business development objectives, we will continue to diligently source and evaluate new biomarkers, diagnostic technologies and opportunities for in-licensing and collaboration with clinicians, researchers and companies in an effort to optimize our technology offering.